Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma

American Journal of Pathology

Volumn 166, Issue 3, 2005, Pages 831-841

  Von Felbert, Verena ^a   Córdoba, Francisco ^a   Weissenberger, Jakob ^a   Vallan, Claudio ^a   Kato, Masashi ^b   Nakashima, Izumi ^c   Braathen, Lasse Roger ^a   Weis, Joachim ^a,d,e  

^a UNIVERSITY OF BERN   (Switzerland)

^b KANAZAWA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; MELANOMA; MELANOSIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TRANSGENIC MOUSE; TUMOR VOLUME;

EID: 14644425398     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62304-8     Document Type: Article

References (66)

1. Marz P, Otten U, Rose-John S: Neuronal activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 1999, 11:2995-3004
2. Kamimura D, Ishihara K, Hirano T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003, 149:1-38
3. Kallen KJ: The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002, 1592:323-343
4. Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse III HC, Kishimoto T, Potter M, Janz S: IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002, 99: 1509-1514
5. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A, Weis J: IL-6 is required for glioma development in a mouse model. Oncogene 2004, 23:3308-3316
6. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z: Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003, 162:655-663
7. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20
8. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105-115
9. Bromberg J: Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res 2000, 2:86-90
10. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008
11. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999, 189:63-73
12. Niu G, Bowman T, Huang M, Shivers S, Reinigen D, Daud A, Chang A, Kraker A, Jove R, Yu H: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21:7001-7010
13. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ: Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991, 96:180-185
14. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS: Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999, 18:1023-1032
15. Fontaine V, Mahieu M, Content J: Interferon-gamma and interleukin-6 inhibit proliferation in human melanoma cells by different signalling pathways. Melanoma Res 1998, 8:24-30
16. Lu C, Vickers MF, Kerbel RS: Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992, 89:9215-9219
17. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 1999, 18:3742-3753
18. Bohm M, Schulte U, Funk JO, Raghunath M, Behrmann I, Kortylewski M, Heinrich PC, Kues T, Luger TA, Schwarz T: Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J Invest Dermatol 2001, 117:132-140
19. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr; 121(2): following 477]. J Cell Biol 1993, 120:1281-1288
20. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr; 121(2): following 477]. J Cell Biol 1993, 120:1281-1288
21. Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP: Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Cancer Res 1995, 55:2200-2205
22. Lee JD, Sievers TM, Skotzko M, Chandler CF, Morton DL, McBride WH, Economou JS: Interleukin-6 production by human melanoma cell lines. Lymphokine Cytokine Res 1992, 11:161-166
23. Francis GM, Krohn EG, Woods KV, Buzaid AC, Grimm EA: Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res 1996, 6:191-201
24. Candi E, Knight RA, Spinedi A, Guerrieri P, Melino G: A possible growth factor role of IL-6 in neuroectodermal tumours. J Neurooncol 1997, 31:115-122
25. Mattel S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M: Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994, 56:853-857
26. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M: Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999, 84:160-168
27. Ciotti P, Rainero ML, Nicolo G, Spina B, Garre C, Casabona F, Santi PL, Bianchi-Scarra G: Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res 1995, 5:41-47
28. Eberlein-Konig B, Jager C, Przybilla B: Ultraviolet B radiation-induced production of interleukin 1alpha and interleukin 6 in a human squamous carcinoma cell line is wavelength-dependent and can be inhibited by pharmacological agents. Br J Dermatol 1998, 139:415-421
29. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C: Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999, 9:181-188
30. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, Khayat D, Soubrane C: Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996, 2:1405-1409
31. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, Montera F, Joyeux I, Pouillart P, Fridman WH: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994, 69:911-913
32. Iwamoto T, Takahashi M, Ito M, Hamatani K, Ohbayashi M, Wajjwalku W, Isobe K, Nakashima I: Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J 1991, 10:3167-3175
33. van den Oord JJ, De Ley M: Distribution of metallothionein in normal and pathological human skin. Arch Dermatol Res 1994, 286:62-68
34. Karasawa M, Nishimura N, Nishimura H, Tohyama C, Hashiba H, Kuroki T: Localization of metallothionein in hair follicles of normal skin and the basal cell layer of hyperplastic epidermis: possible association with cell proliferation. J Invest Dermatol 1991, 97:97-100
35. Miles AT, Hawksworth GM, Beattie JH, Rodilla V: Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 2000, 35:35-70
36. Kato M, Takeda K, Kawamoto Y, Tsuzuki T, Dai Y, Nakayama S, Toriyama K, Tamada Y, Takahashi M, Nakashima I: RET tyrosine kinase enhances hair growth in association with promotion of melanogenesis. Oncogene 2001, 20:7536-7541
37. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I: Transgenic mouse model for skin malignant melanoma. Oncogene 1998, 17:1885-1888
38. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342
39. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Hague SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413
40. Thier M, Marz P, Otten U, Weis J, Rose-John S: Interleukin-6 (IL-6) and its soluble receptor support survival of sensory neurons. J Neurosci Res 1999, 55:411-422
41. Sowalsky RA, Fox BS: Pattern of lectin binding to murine T lymphocytes. Immunology 1992, 75:92-98
42. Kao WW, Prockop DJ: Praline analogue removes fibroblasts from cultured mixed cell populations. Nature 1977, 266:63-64
43. Rakemann T, Niehof M, Kubicka S, Fischer M, Manns MP, Rose-John S, Trautwein C: The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J Biol Chem 1999, 274:1257-1266
44. Thier M, Simon R, Kruttgen A, Rose John S, Heinrich PC, Schroder JM, Weis J: Site-directed mutagenesis of human CNTF: functional analysis of recombinant variants. J Neurosci Res 1995, 40:826-835
45. Weinstein IB: Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64
46. Krasilnikov M, Ivanov VN, Dong J, Ronai Z: ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003, 22: 4092-4101
47. Gonzalez I, Tripathi G, Carter EJ, Cobb LJ, Salih DA, Lovett FA, Holding C, Pell JM: Akt2, a novel functional link between p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in myogenesis. Mol Cell Biol 2004, 24:3607-3622
48. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE: Stat3 as an oncogene. Cell 1999, 98:295-303
49. Birkenkamp KU, Esselink MT, Kruijer W, Vellenga E: An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. Exp Hematol 2000, 28:1239-1249
50. Kuo ML, Chuang SE, Lin MT, Yang SY: The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001, 20:677-685
51. Hideshima T, Nakamura N, Chauhan D, Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000
52. Leu CM, Wong FH, Chang C, Huang SF, Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003, 22:7809-7818
53. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527
54. Masui T, Hosotani R, Doi R, Miyamoto Y, Tsuji S, Nakajima S, Kobayashi H, Koizumi M, Toyoda E, Tulachan SS, Imamura M: Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res 2002, 22:4093-4100
55. Loeffler S, Fayard B, Weis J, Weissenberger J: IL-6 induces transcriptional activation of vascular endothelial growth factor in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and SP1. Int J Cancer (in press)
56. Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H: Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. Exp Hematol 1992, 20:395-400
57. Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J, Wiznerowicz M, Hawley RG, Heinrich PC, Rose John S: Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 1995, 6:805-811
58. Kitamura Y, Morita I, Nihei Z, Mishima Y, Murota S: Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers. Surg Today 1997, 27:534-541
59. Garcia de G, Boyano D, Smith-Zubiaga I, Alvarez A, Canton I, Canavate L: Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells. Eur Cytokine Netw 1998, 9:187-192
60. Mackiewicz A, Wiznerowicz M, Roeb E, Karczewska A, Nowak J, Heinrich PC, Rose John S: Soluble interleukin 6 receptor is biologically active in vivo. Cytokine 1995, 7:142-149
61. Katz A, Shulman LM, Porgador A, Revel M, Feldman M, Eisenbach L: Abrogation of B16 melanoma meetastases by long-term low-dose interleukin-6 therapy. J Immunother 1993, 13:98-109
62. Molinero A, Penkowa M, Hernandez J, Camats J, Giralt M, Lago N, Carrasco J, Campbell IL, Hidalgo J: Metallothionein-I overexpression decreases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin-6. J Neuropathol Exp Neurol 2003, 62:315-328
63. Sato M, Yamaki J, Hamaya M, Hojo H: Synergistic induction of metallothionein synthesis by interleukin-6, dexamethasone and zinc in the rat. Int J Immunopharmacol 1996, 18:167-172
64. Nishimura N, Reeve VE, Nishimura H, Satoh M, Tohyama C: Cutaneous metallothionein induction by ultraviolet B irradiation in interleukin-6 null mice. J Invest Dermatol 2000, 114:343-348
65. Chojnacki A, Shimazaki T, Gregg C, Weinmaster G, Weiss S: Glycoprotein 130 signaling regulates Notch1 expression and activation in the self-renewal of mammalian forebrain neural stem cells. J Neurosci 2003, 23:1730-1741
66. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004, 64:5270-5282